Akebia Therapeutics announced positive topline results from the VOCAL trial showing that vadadustat, given three times a week, is non-inferior to erythropoiesis-stimulating agents (ESA) in maintaining hemoglobin levels in chronic kidney disease (CKD) patients on hemodialysis. The trial also showed similar rates of serious adverse events between vadadustat and ESA. These results add to existing evidence supporting vadadustat's safety and efficacy, complementing previous trials like VOICE and FO2CUS. The findings may influence treatment decisions for anemia in dialysis patients, with vadadustat offering a potential alternative dosing schedule to the once-daily approved regimen.
Akebia Therapeutics' recent VOCAL trial results come amid a health sector where 94 of 150 US stocks traded on Pluang rose today. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: Adaptive Biotechnologies Corp (ADPT) rose 4.79% to USD 27.99 with 100% buy order activity and a typical hold time of 37 days; Brookdale Senior Living Inc. (BKD) fell 4.47% to USD 10.69 with a 21-day hold time; Takeda Pharmaceutical (TAK) increased 3.51% to USD 21.80 with 100% sell order activity and an 18-day hold time.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
